Browse the corpus

Heroin toxicity is a life-threatening emergency caused by excessive activation of opioid receptors following the use of heroin, a powerful opioid derived from morphine. After administration, heroin is rapidly metabolized to morphine and 6-monoacetylmorphine, producing profound central nervous system and respiratory depression. Patients commonly present with slow or absent respirations, decreased consciousness, and pinpoint pupils, though findings may vary with coingestants such as alcohol, benzodiazepines, sympathomimetics, or anticholinergics. Management focuses on airway protection, ventilatory support, and administration of naloxone, an opioid antagonist that reverses respiratory depression. Ongoing care includes assessment for opioid use disorder, harm reduction interventions, and coordinated referral for addiction treatment and recovery support. This activity for healthcare professionals is designed to enhance the learners' understanding of the pathophysiology, recognition, and management of heroin toxicity while fostering practical, patient-centered approaches to improve outcomes. Participants will strengthen their ability to identify key clinical features of heroin toxicity, such as respiratory depression, altered mental status, and miosis, and implement evidence-based interventions, including airway management, naloxone use, and post-reversal monitoring. Clinicians will also gain insight into effective harm reduction and relapse prevention strategies, such as naloxone distribution, initiation of medication-assisted treatment, and patient and family education on overdose prevention. By emphasizing interprofessional communication and coordinated care among physicians, advanced practitioners, nurses, pharmacists, and behavioral health professionals, this activity further enhances participants' ability to deliver compassionate, evidence-based treatment, improve team performance, reduce recurrent overdose, and promote long-term patient safety and recovery. Objectives: Identify the signs and symptoms of acute heroin toxicity, including respiratory depression, altered mental status, and miosis. Differentiate heroin toxicity from other causes of central nervous system and respiratory depression, such as benzodiazepine or alcohol toxicity. Implement evidence-based emergency interventions, including airway management and timely administration of naloxone.

Identify the signs and symptoms of acute heroin toxicity, including respiratory depression, altered mental status, and miosis. Differentiate heroin toxicity from other causes of central nervous system and respiratory depression, such as benzodiazepine or alcohol toxicity. Implement evidence-based emergency interventions, including airway management and timely administration of naloxone. Collaborate with emergency medicine, toxicology, addiction medicine, nursing, and pharmacy teams to optimize patient outcomes. Access free multiple choice questions on this topic.

Heroin toxicity is a life-threatening medical emergency caused by excessive activation of opioid receptors following heroin use. Heroin, or diacetylmorphine, is a potent opioid derived from morphine that exerts its toxic effects primarily through suppression of the central nervous and respiratory systems. Once administered, either through injection, nasal insufflation, or inhalation, heroin is rapidly metabolized to 6-monoacetylmorphine (6-MAM) and morphine, which bind to μ-opioid receptors in the brainstem and peripheral tissues, inhibiting respiratory drive leading to hypoventilation, hypoxia, and potentially death.[1] The unpredictability of heroin’s potency, contamination with synthetic opioids such as fentanyl, coingestion of alcohol or benzodiazepines, and reduced tolerance after periods of abstinence significantly increase overdose risk.[2][3][4] Clinically, patients with heroin toxicity may present with altered mental status, slow or shallow respirations, miosis, hypothermia, hypotension, or evidence of aspiration and pulmonary edema. Severe cases can progress to apnea, coma, and cardiac arrest within minutes if not promptly recognized and treated. Initial management focuses on airway stabilization, ventilatory support, and administration of naloxone, titrated to restore adequate respirations.[5] Equally as crucial is long-term management following acute treatment. Assessing patients for opioid use disorder (OUD), initiating medication-assisted treatment with agents such as buprenorphine or methadone, and implementing harm reduction measures, such as naloxone distribution and connection to recovery services, can significantly reduce the morbidity and mortality associated with OUD.[6] A coordinated, interprofessional approach that emphasizes compassion and avoids stigma enhances patient engagement, decreases the likelihood of recurrent overdose, and promotes long-term recovery and safety.

The etiology of heroin toxicity is the binding of heroin and its metabolites to μ-opioid receptors in the brain, which suppresses the central nervous and respiratory systems. These effects, combined with factors such as unknown purity and the concomitant use of other substances, may result in life-threatening respiratory depression and overdose. Additional risk factors contributing to the toxicity and risk of heroin overdose are as follows: Unknown purity and the addition of unknown substances, including fentanyl, quinine, heavy metals, or possibly infectious agents. As an individual continues to use heroin, their tolerance increases, resulting in the need for continually increased doses. Following a period of abstinence, such as incarceration or sobriety, if they return to their previous dose, overdose can occur. Coingestion of heroin with other CNS depressants such as benzodiazepines or alcohol increases the risk of respiratory depression. Injecting heroin allows the drug to reach the brain quickly, increasing the risk of respiratory depression. Concurrent medical conditions such as chronic obstructive pulmonary disease (COPD), sleep apnea, or liver and kidney disease can increase susceptibility to overdose.[7]

According to the Substance Abuse and Mental Health Services Administration, nearly 2.3% of people in the United States, 12 or older, have used heroin at some point in their lives. In the United States, the prevalence of heroin use disorder doubled between 2002 and 2018.[8] However, the incidence of heroin related overdose deaths decreased from 15,000 in 2018 to 6000 in 2022. Heroin use disorder is most common in men, young adults 18 to 29, and non-Hispanic White individuals. The strongest risk factor is prior nonmedical use of prescription opioids.[9][10] Additional risk factors for heroin use disorder are psychiatric comorbidities such as depression, PTSD, and personality disorders, social disadvantage, and recent release from institutional settings such as incarceration or substance use treatment facilities.[11]

The pathophysiology underlying heroin toxicity is primarily due to its rapid conversion to active metabolites that act as potent opioid receptor agonists, central nervous system, and respiratory depressants. After administration, heroin quickly metabolizes to 6-MAM and morphine, both of which bind to μ-opioid receptors in the periphery and the areas of the brain that control respiration, mood, and pain. When morphine binds to the opioid receptors on these GABAergic neurons, it inhibits them from releasing GABA. This receptor activation in the brainstem inhibits the medullary respiratory centers and peripheral chemoreceptors, resulting in decreased respiratory drive, hypoventilation, and hypoxia.[12][13] Secondary mechanisms involved in heroin toxicity involve a neuroinflammatory response, neuronal apoptosis, and organ toxicity. Hypoxic-ischemic brain injury from respiratory depression triggers the release of cytokines and activation of microglia, contributing to further neuronal damage.[14] Additionally, heroin and its metabolites can induce mitochondrial dysfunction and apoptosis in neurons via caspase activation and the c-Jun N-terminal kinase (JNK/c-Jun) signaling pathway, an essential component of the cellular response to stress that helps regulate cell survival and apoptosis.[15] Chronic or high-dose exposure to heroin may also cause hepatotoxicity, rhabdomyolysis, renal failure, as well as rare complications like leukoencephalopathy and myelitis.[16] Coadministration with other CNS depressants, such as alcohol and benzodiazepines, can potentiate respiratory depression due to overlapping inhibitory effects on GABA and glutamate neurotransmission.

Classic physical examination findings of acute heroin intoxication are depressed mental status, respiratory rate, tidal volume, and bowel sounds, along with miosis. A respiratory rate below 12/breaths per minute is the best predictor of opioid toxicity.[18] The absence of miosis does not exclude heroin toxicity, as coingestion of sympathomimetics or anticholinergics may make the pupils appear normal or enlarged. Some potential additional findings are as follows: Hypothermia due to environmental exposure and impaired thermogenesis; Seizures due to hypoxia; Hyperthermia due to aspiration pneumonia or endocarditis; Hypoxia; Mild hypotension due to histamine release; Trauma and TBI (may be mistaken as obtundation due to heroin toxicity); Crackles on lung examination due to aspiration or ARDS; Medication patches on the skin; Chronic soft tissue infections; and Needle marks indicating chronic injection drug use.[19] A severe overdose can progress to apnea with coma, which is followed within minutes by cardiac arrest and death unless immediate rescue measures are taken.[20]

The initial evaluation begins with an immediate assessment of the patient's airway, breathing, and circulation. Clinicians should measure temperature, respiratory rate (including evaluating chest wall excursion), pulse oximetry, heart rate, and blood pressure. Capnography measures end-tidal CO2. The initial diagnosis is clinical, based on the presence of respiratory depression, miosis, and altered mental status, though not all features may be present. Clinicians should attempt to discover the specific drug or medication ingested, the possible presence of any coingestants, if the patient has a history of opioid or substance use disorder, and the reason for poisoning. Clinicians should also obtain a rapid blood glucose level, a serum acetaminophen level if coingestion or with suspicion of self-harm, and a serum creatine phosphokinase level to exclude rhabdomyolysis in the setting of prolonged immobilization.[21] Additional laboratory tests may include serum creatinine and electrolytes. A urine toxicology screen is unnecessary, as the management of acute heroin toxicity will not change based on the results. A positive test only indicates recent use and not acute intoxication, or it may be a false positive. Additionally, patients who ingest some synthetic opioids will have a false negative result. Patients with suspected coingestion of cyclic antidepressants or self-harm should undergo an ECG, and chest radiography is necessary in patients with suspected aspiration, ARDS, or those who continue to have hypoxia despite correction of hypoventilation. A plain abdominal radiograph or ultrasound, followed by abdominal computed tomography (CT) or barium-enhanced studies, may be necessary in patients suspected of body packing. On the secondary survey, clinicians should evaluate for trauma and traumatic brain injury, secondary skin infections, and any other potential complications such as endocarditis. Additionally, and only with the patient's permission, with suspected body packing, a rectal and vaginal examination may be necessary. In a comatose patient, consent is implied; however, the examination is solely for diagnostic and treatment purposes, not for evidence collection for law enforcement.

Initial management centers around airway, breathing, and circulation. Pulse oximetry is a good measure of oxygenation, but not a valuable tool for monitoring a patient's ventilation while they receive supplemental oxygen. Naloxone is a mainstay of therapy to reverse the effects of heroin toxicity.[22] Apnea or impending respiratory arrest:  Administer 0.2 to 1 mg of intravenous (IV) naloxone. Patients who experience cardiopulmonary arrest should receive 2 mg of naloxone. In patients who are apenic, have very shallow respirations, or very low respiratory rates, clinicians should establish oxygenation with a bag valve mask before administering naloxone to help prevent ARDS. Patients with spontaneous respirations: Administer 0.04 or 0.08 mg of naloxone intravenously, and continue upward titration every few minutes until the respiratory rate exceeds 12 breaths per minute. The goal is adequate ventilation, not normal consciousness. If the patient does not have IV access, alternative routes of naloxone administration include nasal, subcutaneous, intramuscular, or intraosseous. Depending on the opioid causing toxicity, repeat dosing or an infusion of naloxone may be necessary. If the patient has not ingested any additional substances or other opioids, there is minimal risk of rebound opioid effects. After observing the patient for one hour, clinicians can safely discharge them if they can ambulate normally, maintain stable vital signs, and have a Glasgow Coma Score of 15.[23]

If the patient does not have IV access, alternative routes of naloxone administration include nasal, subcutaneous, intramuscular, or intraosseous. Depending on the opioid causing toxicity, repeat dosing or an infusion of naloxone may be necessary. If the patient has not ingested any additional substances or other opioids, there is minimal risk of rebound opioid effects. After observing the patient for one hour, clinicians can safely discharge them if they can ambulate normally, maintain stable vital signs, and have a Glasgow Coma Score of 15.[23] Clinicians are encountering increasingly variable intensity and duration of opioid effects due to the presence of potent synthetic analogs such as fentanyl and nitazenes in the illicit drug supply. This variability has made it more difficult to predict the effective naloxone dose or duration of monitoring required to prevent re-sedation after reversal. Concerns have also arisen about naloxone availability, as larger or repeated doses are often required to reverse these newer synthetic opioids. Some experts have proposed that, in some instances of prolonged toxicity, management should prioritize airway protection and mechanical ventilation until spontaneous respiration resumes, rather than relying solely on repeated naloxone administration. However, most toxicology and emergency medicine guidelines continue to emphasize that naloxone remains effective for all opioids, including fentanyl analogs, when given in adequate doses and with appropriate ongoing observation and supportive care.

The differential diagnoses for a patient who is unresponsive are extensive. Some potential diagnoses are as follows: Multiple drug toxicities, including benzodiazepines, lithium, baclofen, and hypoglycemic agents Carbon monoxide toxicity Stroke Cyanide toxicity Hypoglycemia Hypoxia Hypercarbia Hypocalcemia Hypothyroidism Hypothermia Liver failure Renal failure Encephalitis Sepsis Status epilepticus Elevated intracranial pressure due to abscess, tumor, or edema Traumatic brain injury Systemic hypotension Cardiac arrest

The pharmacologic action of heroin on opioid receptors is well characterized. An ongoing area of forensic investigation involves identifying opioid contaminants that may be present in heroin shipments entering the United States. Many of these adulterants, such as carfentanil, are not detected on standard drug screens. Gas chromatography–mass spectrometry (GC–MS) is often required to determine the exact composition of a sample.[24] Some interest exists in evaluating whether cannabis could serve as a harm reduction alternative for patients with heroin use disorder, given its substantially lower risk of fatal overdose compared to heroin.[25] However, no current high-quality evidence from randomized controlled trials supports that cannabis is effective or safe as a harm reduction strategy for reducing opioid use or overdose risk in patients with heroin use disorder. Further studies are necessary. The latest clinical trial data indicate that buprenorphine is as effective as naloxone for reversing opioid-induced respiratory depression in opioid-dependent patients, with a lower incidence of acute opioid withdrawal and reduced need for intubation or repeated antagonist dosing. Naloxone remains the first-line agent per current guidelines, as further studies are needed to define optimal dosing and the broader applicability of buprenorphine.[26][27]

Heroin use disorder is a chronically relapsing disorder with a mortality rate 6 to 20 times higher than the general population, with overdose, infectious disease, and cardiovascular complications as the leading causes of death.[37][38] Less than 30% of patients maintain abstinence at 10 and 30 years.[37] However, continuous engagement in opioid substitution treatment, such as methadone, buprenorphine, or naltrexone, is associated with significant reductions in heroin use, criminality, risk-taking, and improvements in physical and mental health.[39][40][41][42] Major depressive disorder and lack of social support are predictors of poorer outcomes, while employment and psychosocial interventions improve overall prognosis.

The most immediate and life-threatening complication of heroin toxicity is respiratory depression, which can progress to hypoxic brain injury and death if not rapidly reversed. Additional complications are as follows: Noncardiogenic pulmonary edema; Aspiration pneumonia; Rhabdomyolysis; Compartment syndrome; Acute renal failure due to prolonged immobilization; Toxic leukoencephalopathy; Seizure; Stroke; Transverse myelitis; Peripheral neuropathy; Cellulitis; Abscesses; Endocarditis; Hepatitis B and C; HIV; Tuberculosis; Constipation; Venous sclerosis and chronic venous insufficiency; and Reproductive dysfunction.[43][44][45]

Clinicians play a vital role in reducing heroin-related morbidity and mortality through prevention, patient education, and linkage to ongoing care. After ingestion, heroin rapidly metabolizes to morphine, which binds to μ-opioid receptors, producing euphoria, analgesia, and marked central nervous system effects. Excessive receptor activation leads to profound respiratory and central nervous system depression, which may progress to hypoxia, coma, or death. Most heroin toxicity occurs among experienced users, often involving co-ingestion of alcohol, benzodiazepines, or other sedatives, or following a period of abstinence, such as after incarceration or discharge from a treatment program, when tolerance to opioids has diminished.The unpredictable potency of illicit heroin, largely due to contamination with synthetic opioids such as fentanyl and its analogs, significantly increases the risk of fatal toxicity. Patients experiencing heroin toxicity typically present with miosis, shallow or absent respirations, decreased level of consciousness, cyanosis, and cold, clammy skin. Prompt recognition of these signs and the immediate administration of naloxone are critical and often lifesaving. Clinicians should educate patients and their families about the warning signs of overdose, proper use of naloxone, and ensure access to take-home kits or prescriptions for emergency use. Additional harm reduction interventions include referral to syringe service programs, medication-assisted treatment options such as buprenorphine or methadone, and counseling or peer support networks. Emphasizing that recovery is achievable and providing care in a confidential, nonjudgmental environment helps reduce stigma and promote engagement. Education should also address relapse prevention and trigger management, including strategies for coping with stress, pain, or environmental cues. Clinicians should encourage safe disposal of drug-use equipment and secure medication storage to prevent diversion. Through empathetic communication and interprofessional collaboration among addiction medicine and behavioral health specialists, pharmacists, nurses, and social workers, clinicians can empower patients to adopt safer practices, seek treatment early, and help break the cycle of overdose and reinjury.

Heroin is a potent opioid prodrug derived from morphine ingested by inhalation, smoking, or injection. Heroin is more lipid-soluble than morphine, allowing for rapid central nervous system penetration and potent euphoric effects. Once ingested, heroin is rapidly metabolized to 6-MAM and subsequently to morphine, both of which activate μ-opioid receptors. Toxicity results from excessive central nervous system and respiratory depression secondary to μ-opioid receptor activation. Overdoses often occur in experienced users, especially following periods of abstinence or co-ingestion with depressants such as alcohol or benzodiazepines. Patients typically present with depressed mental status, shallow or absent respirations, decreased bowel sounds, and pinpoint pupils, though pupil size may vary with coexposures. Complications include hypoxia, aspiration, pulmonary edema, and ARDS, the latter sometimes following rapid naloxone reversal. Management centers on airway protection, assisted ventilation, and administration of naloxone, titrated to restore adequate respiratory effort rather than full arousal. Continuous pulse oximetry and capnography help monitor ventilation and oxygenation. Supportive care includes managing hypothermia, hypoglycemia, and aspiration risk. Once stabilized, patients should be screened for OUD and linked to addiction treatment and harm reduction services to reduce the risk of recurrence.

Heroin is a potent opioid prodrug derived from morphine ingested by inhalation, smoking, or injection. Heroin is more lipid-soluble than morphine, allowing for rapid central nervous system penetration and potent euphoric effects. Once ingested, heroin is rapidly metabolized to 6-MAM and subsequently to morphine, both of which activate μ-opioid receptors. Toxicity results from excessive central nervous system and respiratory depression secondary to μ-opioid receptor activation. Overdoses often occur in experienced users, especially following periods of abstinence or co-ingestion with depressants such as alcohol or benzodiazepines. Patients typically present with depressed mental status, shallow or absent respirations, decreased bowel sounds, and pinpoint pupils, though pupil size may vary with coexposures. Complications include hypoxia, aspiration, pulmonary edema, and ARDS, the latter sometimes following rapid naloxone reversal. Management centers on airway protection, assisted ventilation, and administration of naloxone, titrated to restore adequate respiratory effort rather than full arousal. Continuous pulse oximetry and capnography help monitor ventilation and oxygenation. Supportive care includes managing hypothermia, hypoglycemia, and aspiration risk. Once stabilized, patients should be screened for OUD and linked to addiction treatment and harm reduction services to reduce the risk of recurrence. Comprehensive care extends beyond the acute episode. Coordination across inpatient and outpatient settings ensures that patients are not only stabilized but also linked to harm reduction programs, MAT clinics, and psychosocial support networks. Physicians and advanced practitioners develop discharge plans that include naloxone distribution, overdose prevention education, and follow-up appointments. Nurses reinforce these instructions, assess readiness for change, and provide motivational support. Pharmacists review medication regimens to prevent dangerous drug combinations, while behavioral health specialists and social workers facilitate ongoing therapy, recovery resources, and community-based follow-up. When care teams operate cohesively, outcomes improve across multiple dimensions, including faster response times during overdose management, reduced incidence of complications, better treatment adherence, and lower rates of recurrent overdose. Interprofessional teamwork fosters trust, reduces stigma, and creates a supportive environment where patients feel respected and motivated to engage in treatment. Collaborative reflection and debriefing after overdose events also strengthen team performance, highlight opportunities for process improvement, and reinforce a culture of patient safety. Through shared expertise, coordinated communication, and unified commitment to compassionate care, healthcare teams can transform acute heroin toxicity encounters into opportunities for recovery, prevention, and long-term improvement in both patient health and system-level performance.